MetaCap

Adicet Bio (ACET) vs Cocrystal Pharma (COCP)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cocrystal Pharma (COCP) has outperformed Adicet Bio (ACET) over the past year, gaining 5.6% versus a loss of 77.8%. Over five years, COCP leads with a -91.8% price change compared with -98.6% for ACET. Adicet Bio is the larger company by market cap ($20.0 million vs $18.3 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ACET-77.78%COCP+5.56%
+82%-2%-85%
Nov 21, 20251 yearNov 20, 2026
ACET-98.56%COCP-90.35%
+140%+15%-110%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ACET versus COCP key metrics
MetricACETCOCP
Share price$2.14$0.95
Market cap$20.03M$18.30M
1-day change-13.01%-2.05%
YTD return-74.58%-3.06%
1-year return-77.78%+5.56%
5-year return-98.58%-91.84%
EPS (TTM)$-7.53$-0.76
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Net income (latest FY)$-116.80M$-8.83M
52-week high$11.15$2.03
52-week low$2.12$0.76
Distance from 52-week high-80.81%-53.20%
Analyst consensusstrong_buynone
Avg. price target upside+1527.57%+847.37%
Average volume271.05K40.65K
Shares outstanding9.36M19.26M
Employees10210
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • COCP has outperformed ACET by 83.3 percentage points over the past year.

About Adicet Bio

ACET stock →

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 102 employees

About Cocrystal Pharma

COCP stock →

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases in the United States. The company employs structure-based technologies to create antiviral drugs including influenza virus, norovirus, coronaviruses, such as SARS-CoV-2 and MERS-CoV, as well as respiratory virus infections, and hepatitis C virus (HCV) infections.

Health Care · Biotechnology: Pharmaceutical Preparations · 10 employees

ACET vs COCP FAQ

Which is bigger, Adicet Bio or Cocrystal Pharma?

Adicet Bio (ACET) is larger, with a market capitalization of $20.03M compared with $18.30M for Cocrystal Pharma (COCP).

Which stock has performed better over the past year, ACET or COCP?

COCP returned +5.56% over the past 12 months, compared with -77.78% for ACET (price return, excluding dividends). Past performance does not predict future results.

Are Adicet Bio and Cocrystal Pharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons